In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Almirall SA

www.almirall.es

Latest From Almirall SA

Finance Watch: Five IPOs Launch In Two Days; Three Remain In Positive Territory

Public Company Edition: Trevi Therapeutics was the first out of the gate on 7 May, but four more biopharma firms went public in the US on 8 May, while just 13 IPOs launched between January and April. Also, new financings include debt for BMS, Bausch and Intercept.

Financing Business Strategies

Deal Watch: Celgene Joins Line Of Partners Tapping Exscientia’s AI-Driven Discovery Engine

While the proposed Bristol/Celgene merger nears an April vote, Celgene continues a recent spate of deal-making, paying $25m up front to Exscientia to discover small molecule candidates for cancer and autoimmune disease.

Business Strategies Commercial

Dermira’s Lebrikizumab Data Set Up Atopic Dermatitis Showdown With Dupixent

Dermira hopes to move into Phase III quickly with IL-13 inhibitor lebrikizumab, looking at monthly dosing in the maintenance setting. Efficacy in Phase IIb appears similar to Sanofi/Regeneron’s Dupixent.

Clinical Trials Dermatology

Galderma’s First-In-Class Biologic Chases Eczema Spoils

Galderma’s novel biologic is heading for Phase III studies in moderate-to-severe atopic dermatitis as the race to join Dupixent in an expanding market hots up.

Clinical Trials Dermatology
See All

Company Information

  • Industry
  • Medical Devices
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Dermatology
  • Neurology, Nervous System
  • Respiratory, Pulmonary
  • Alias(es)
  • Almirall Prodesfarma SA
  • Laboratorios Almirall SA
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Spain
  • Parent & Subsidiaries
  • Almirall SA
  • Senior Management
  • Eduardo Sanchiz Yrazu, CEO
    Jorge Gallardo Ballart, Pres.
  • Contact Info
  • Almirall SA
    Phone: (34) 93 291 30 00
    Ronda General Mitre, 151
    Barcelona, 08022
    Spain
Advertisement
Advertisement
UsernamePublicRestriction

Register